The dopamine-depleting effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in CD-1 mice are gender-dependent

Brain Research

Volumn 735, Issue 2, 1996, Pages 232-238

  Freyaldenhoven, Tim E ^a,b   Cadet, Jean L ^c   Ali, Syed F ^a,b  

^a National Center for Toxicology Research   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c NIDA Addiction Research Center   (United States)

Author keywords

CD 1 mouse; Gender; MPP+; MPTP; Neurotoxicity; Striatal dopamine

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC SYSTEM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0030574076     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00598-7     Document Type: Article

References (44)

1. + induced oxygen radical formation with mitochondrial enzymes, Free Rad. Biol. Med., 15 (1993) 181-186.
2. [2] Ali, S.F., David, S.N. and Newport, G.D., Age-related susceptibility to MPTP-induced neurotoxicity in mice, Neurotoxicology, 14 (1993) 29-34.
3. [3] Ali, S.F., David, S.N., Newport, G.D., Cadet, J.L. and Slikker, W., Jr., MPTP-induced oxidative stress and neurotoxicity are age-dependent: Evidence from measures of reactive oxygen species and striatal dopamine levels, Synapse, 18 (1994) 27-34.
4. [4] Boyce, S., Kelly, E., Reavill, C., Jenner, P. and Marsden, C.D., Repeated administration of N-methyl-1,2,3,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones, Biochem. Pharmacol., 33 (1984) 1747-1752.
5. [5] Burns, R.S., Chiueh, C.C., Markey, S.P., Ebert, M.H., Jacobowitz, D.M. and Kopin, I.J., A primate model of parkinsonism: selective destruction of dopaminergic neurons in pars compacta of the substantia nigra by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Proc. Natl. Acad. Sci. USA, 80 (1983) 4546-4550.
6. [6] Cadet, J.L., Ladenheim, B., Hirata, H., Rothman, R.B., Ali, S., Carlson, E., Epstein, C. and Moran, T.H., Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): Evidence from using CuZn-superoxide dismutase transgenic mice, Synapse, 21 (1995) 169-176.
7. [7] Chan, P., DeLanney, L.E., Irwin, I., Langston, J.W. and DiMonte, D., Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain, J. Neurochem., 57 (1991) 348-351.
8. [8] Chiueh, C.C., Miyake, H. and Peng, M., Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced Parkinsonism, Adv. Neurol., 60 (1993) 251-258.
9. [9] Cooper, J.R., Bloom, F.E. and Roth, R.H., The Biochemical Basis of Neuropharmacology, 6th edn., Oxford University Press, New York, 1991.
10. [10] Davis, G.C., Williams, A.C., Markey, S.P., Ebert, M.H., Caine, E.D., Reihert, C.M. and Kopin, I.J., Chronic parkinsonism secondary to intravenous injection of meperidine analogs, Psychol. Res., 1 (1979) 249-254.
11. +-induced neurotoxicity in mouse is age-dependent: evidence by the selective inhibition of complexes of electron transport, Brain Res., 715 (1996) 1-8.
12. + cause rapid ATP depletion in isolated hepatocytes, Biochem. Biophys. Res. Commun., 137 (1986) 310-315.
13. [13] Forno, L.S., DeLanney, L.E., Irwin, I. and Langston, J.W., Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease; Neuropathological considerations, Adv. Neurol., 60 (1993) 600-608.
14. [14] Giovanni, A., Sieber, B.A., Heikkila, R.E. and Sonsalla, P.K., Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice, J. Pharmacol. Exp. Ther., 257 (1991) 691-697.
15. [15] Giovanni, A., Sieber, B.A., Heikkila, R.E. and Sonsalla, P.K., Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration, J. Pharmacol. Exp. Ther., 270 (1994) 1000-1007.
16. [16] Giovanni, A., Sonsalla, P.K. and Heikkila, R.E., Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium, J. Pharmacol. Exp. Ther., 270 (1994) 1008-1014.
17. 3H-DOPA in various regions of the brain, J. Neurochem., 13 (1966) 655-669.
18. [18] Graybiel, A.M., Moratallia, R., Quinn, B., Delanney, L.E., Irwin, I. and Langston, J.W., Early stage loss of dopamine uptake site binding in MPTP-treated monkey, Adv. Neurol., 60 (1993) 34-39.
19. [19] Hallman, H., Lange, J., Olson, L., Stromberg, I. and Jonsson, G., Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse, J. Neurochem., 44 (1985) 117-127.
20. [20] Harik, S.I., Riachi, N.J. and LaManna, J.C., MPTP neurotoxicity and the 'biochemical' blood-brain barrier. In F. Hefti and W.J. Weiner (Eds.), Progress in Parkinson Research, Plenum Press, New York, 1988, pp. 93-100.
21. [21] Heikkila, R.E., Differential neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Swiss-Webster mice from different sources, Eur. J. Pharmacol., 117 (1985) 131-133.
22. [22] Heikkila, R.E., Hess, A. and Duvoisin, R.D., Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice, Science, 224 (1984) 1451-1453.
23. [23] Heikkila, R.E., Manzino, L., Cabbat, F.S. and Duvoisin, R.C., Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors, Nature, 311 (1984) 467-469.
24. [24] Javitch, J.A., D'Amato, R.J., Strittmatter, S.M. and Snyder, S.H., Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity, Proc. Natl. Acad. Sci. USA, 82 (1985) 2173-2177.
25. [25] Kalaria, R.N., Mitchell, M.J. and Harik, S.I., Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity, Proc. Natl. Acad. Sci. USA, 84 (1987) 3521-3525.
26. [26] Kurtzke, J.F. and Goldberg, J.D., Parkinsonism death rates by race, sex, and geography, Neurology, 38 (1988) 1558-1561.
27. [27] Langston, J.W., Ballard, P., Tetrud, J.W. and Irwin, I., Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis, Science, 219 (1983) 979-980.
28. +: Identification of a metabolite of MPTP, a toxin selective to the substantia nigra, Neurosci. Lett., 48 (1984) 87-92.
29. + toxicity encodes a vessicular amine transporter, Cell, 70 (1992) 539-551.
30. [30] Mayeux, R., Denaro, J., Hemenegildo, N., Marder, K., Tang, M.-X., Cato L.J. and Stern, Y., A population based investigation of Parkinson's disease with and without dementia, Arch. Neurol., 49 (1992) 492-497.
31. [31] McDermott, J.L., Liu, B. and Dluzen, D.E., Sex differences and effects of estrogen on dopamine and DOPAC release from the striatum of male and female CD-1 mice, Exp. Neurol., 125 (1994) 306-311.
32. [32] Naoi, M., Takahashi, T. and Nagatsu, T., A fluorometric determination of N-methyl-4-phenylpyridinium ion, using high-performance liquid chromatography, Anal. Biochem., 162 (1987) 540-545.
33. [33] Niklas, W.J., Vyas, I. and Heikkila, R.E., Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Life Sci., 36 (1985) 2503-2508.
34. [34] Panek, D.U. and Dixon, W.R., Effect of continuous intraventricular estrogen or catechol estrogen treatment on catecholamine turnover in various brain regions, J. Pharmacol. Exp. Ther., 236 (1986) 646-652.
35. [35] Przedborski, S., Kostic, V., Jackson-Lewis, V., Naini, A.B., Simonetti, S., Fahn, S., Carlson, E., Epstein, C.J. and Cadet, J.L., Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to MPTP-induced neurotoxicity, J. Neurosci., 12 (1992) 1658-1667.
36. [36] Ramsay, R.R. and Singer, T.P., Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria, J. Biol. Chem., 261 (1986) 7585-7587.
37. [37] Reinhard, J.F., Jr., Diliberto, E.J., Jr., Viveros, O.K. and Daniels, A.J., Subcellular compartmentalization of 1-methyl-4-phenylpyridinium wiht catecholamines in adrenal medullary chromaffin vessicles may explain the lack of toxicity to adrenal chromaffin cells., Proc. Natl. Acad. Sci. USA, 84 (1987) 8160-8164.
38. [38] Riachi, N.J., LaManna, J.C. and Harik, S.I., Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain, J. Pharmacol. Exp. Ther., 249 (1989) 744-748.
39. [39] Scotcher, K.P., Irwin, I., DeLanney, L.E., Langston, J.W. and DiMonte, D, Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridmium ion on ATP levels of mouse brain synaptosomes, J. Neurochem., 54 (1990) 1295-1301.
40. [40] Sonsalla, P.K. and Heikkila, R.E., The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice, Eur. J. Pharmacol., 129 (1986) 339-345.
41. [41] Tabatabaei, A., Perry, T.L., Hansen, S. and Krieger, C., Partial protective effect of MK-801 on MPTP-induced reduction of striatal dopamine in mice, Neurosci. Lett., 141 (1992) 192-194.
42. + neurotoxicity by N-methyl-D-aspartate antagonists, Nature, 349 (1991) 414-418.
43. [43] Unzeta, M., Baron, S., Perez, V., Ambrosio, S. and Mahy, N., Sex-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment may be related to differences in monoamine oxidase B, Neurosci. Lett., 176 (1994) 235-238.
44. [44] Youngster, S.K., McKeown, K.A., Jin, Y., Ramsay, R.R., Heikkila, R.E. and Singer, T.P., Oxidation of analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase A and B and the inhibition of monoamine oxidases by the oxidation products, J. Neurochem., 53 (1989) 1837-1842.